Repotrectinib Yields Enduring Activity in NTRK+ Solid Tumor Trial
A noteworthy report cues the promising impacts of Repotrectinib on solid tumors expressing NTRK genetic rearrangements.
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
In a significant move, the FDA obstructed a clinical trial assessing Lorigerlimab, research focused on the treatment of gynecologic cancers. The reasons behind this decision are not disclosed in this section.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
Recent discussions in oncology suggest efforts to improve the management of toxic side effects caused by immune-checkpoint inhibitors in melanoma treatment.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
The FDA has expedited the approval process for SRN-101, an innovative drug designed for patients battling recurrent high-grade glioma, highlighting its potential impact.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
Evidence of initial successes has been reported with a novel small molecule drug showing benefits in the treatment of pretreated multiple myeloma.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
A comparative analysis is being conducted to assess the quality of life outcomes between proton and photon treatments in patients diagnosed with oropharyngeal squamous cell carcinoma (OPSCC).
